Publication: Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy
Issued Date
2009-08-12
Resource Type
ISSN
13484214
09169636
09169636
Other identifier(s)
2-s2.0-68249146212
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hypertension Research. Vol.32, No.6 (2009), 520-526
Suggested Citation
Kee Sik Kim, Wei Hu Fan, Young Dae Kim, Wenling Zhu, Yen Yew Ngau, Peter Tong, Byung Soo Kim, Maureen Santos, Wei Hsiang Lin, Peera Buranakitjaroen, Rachid Massaad, Ronald D. Smith Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy. Hypertension Research. Vol.32, No.6 (2009), 520-526. doi:10.1038/hr.2009.42 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/27163
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy
Other Contributor(s)
Catholic University of Daegu
Huashan Hospital
Dong-A University, College of Medicine
Peking Union Medical College
Kuala Lumpur Hospital
Prince of Wales Hospital Hong Kong
Daedong Hospital
Cebu Doctors' University Hospital
Triservice General Hospital Taiwan
Mahidol University
MSD (Europe) Inc.
Merck & Co., Inc.
Huashan Hospital
Dong-A University, College of Medicine
Peking Union Medical College
Kuala Lumpur Hospital
Prince of Wales Hospital Hong Kong
Daedong Hospital
Cebu Doctors' University Hospital
Triservice General Hospital Taiwan
Mahidol University
MSD (Europe) Inc.
Merck & Co., Inc.
Abstract
Antihypertensive efficacy and safety of losartan/hydrochlorothiazide (HCTZ) combinations have not been adequately studied in Asians. In this open-label, 12-week study in seven Asian areas, patients on monotherapy with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) but not at blood pressure (BP) goal (sitting diastolic BP (SiDBP) <90 mm Hg in non-diabetics and <80 mm Hg in diabetics) were switched to losartan 50 mg/HCTZ 12.5 mg. At 4 and 8 weeks, the therapy for patients not at goal BP was titrated to losartan 100 mg/HCTZ 12.5 mg and to losartan 100 mg/HCTZ 25 mg, respectively. Data analysis included 430 patients with mean (s.d.) age 53.0 (10.1) years and 51.9% of the female gender. After 8 weeks (primary end point; titration up to losartan 100 mg/HCTZ 12.5 mg), 73.5% (95% confidence interval (CI): 69.0-77.6) of patients reached BP goal; 63.4 and 78.1% of patients reached BP goal at 4 weeks (titration up to losartan 50 mg/HCTZ 12.5 mg) and at 12 weeks (titration up to losartan 100 mg/HCTZ 25 mg). The mean changes from baseline (95% CI) in sitting systolic BP and SiDBP at 8 weeks were -16.7 (-18.0 to -15.4) mm Hg and -12.1 (-12.9 to -11.4) mm Hg, respectively. Clinical and laboratory adverse experiences (AEs) were reported in 27.5 and 21.0% of patients, respectively. Nine patients were discontinued because of drug-related clinical AEs. Switching Asian patients currently not at BP goal with ARB or ACEI monotherapy to a losartan/HCTZ combination achieved BP goal in the majority of patients. Losartan/HCTZ combinations were generally well tolerated.